Cancer Treatment Reviews
Volume 29, Issue 1 , Pages 69-71, February 2003

Paclitaxel plus gemcitabine may be as active and well tolerated as paclitaxel plus carboplatin for advanced non-small-cell lung cancer☆☆☆★

  • Yuh-Min Chen, md, Phd, fccp Associate Professor, Medical Oncologist and Chest Physician

Hygeia Hospital Athens Greece

Chest Department, School of Medicine, National Yang-Ming University, Taipei Veterans General Hospital, Taiwan

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Sources of funding: none specified

☆☆ For correspondence: P.A. Kosmidis, Hygeia Hospital, Athens, Greece. E-mail: parkosmi@otenet.gr

★ Abstract provided by Bazian Ltd, London

PII: S0305-7372(02)00127-5

doi:10.1016/S0305-7372(02)00127-5

Cancer Treatment Reviews
Volume 29, Issue 1 , Pages 69-71, February 2003

Article Tools